Clinical Trials Logo

Cutaneous Melanoma, Stage IV clinical trials

View clinical trials related to Cutaneous Melanoma, Stage IV.

Filter by:
  • None
  • Page 1

NCT ID: NCT04853602 Available - Clinical trials for Merkel Cell Carcinoma

IFx-Hu2.0 Expanded Access Program

Start date: n/a
Phase:
Study type: Expanded Access

Expanded access requests for IFx-Hu2.0 may be considered for the treatment of adult patients (greater than or equal to 18 years of age) with stage III through IV cutaneous melanoma, advanced Merkel cell carcinoma (MCC), or advanced cutaneous squamous cell carcinoma (cSCC) who have failed all available treatment options. To request access, use Responsible Party contact information provided in this record..

NCT ID: NCT03719131 Active, not recruiting - Clinical trials for Unresectable Melanoma

Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy

Start date: June 5, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies whether rituximab and hyaluronidase human (Rituxan Hycela) can prevent immune related adverse events in participants with stage III-IV melanoma that cannot be removed by surgery who are undergoing nivolumab and ipilimumab therapy.

NCT ID: NCT03663647 Completed - BRAF V600 Mutation Clinical Trials

Advanced Melanoma in Russian Experience

ADMIRE
Start date: October 8, 2018
Phase:
Study type: Observational

Retrospective chart review Study of patients with BRAF V600 positive advanced (unresectable or metastatic) melanoma, who were treated with targeted therapy in routine clinical practice in Russian Federation

NCT ID: NCT03655756 Completed - Clinical trials for Cutaneous Melanoma, Stage IV

pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma

Start date: November 5, 2018
Phase: Early Phase 1
Study type: Interventional

Six patients will receive IFx-Hu2.0 on an outpatient basis at a single time point in a single lesion, two lesions, or three lesions, as a monotherapy (a maximum of three lesions could be injected). These patients will be assessed for any immediate adverse reactions and at Week 4 (Day 28+/-7 business days for any delayed adverse events.